LRMR
Larimar Therapeutics Inc
3.00$
-3.3%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -7.7% | +158.7% | -4.4% | -7.6% | -8.6% | -15.0% | -11.9% | +24.9% | -22.2% | +43.0% | -20.7% | |
| – | -8.4% | +156.1% | +0.1% | -7.7% | -8.4% | -15.3% | -12.0% | +25.9% | -22.5% | +44.3% | -21.6% | |
| – | -30.9% | +311.7% | -70.7% | +8.5% | -5.3% | -36.4% | -2.6% | +337.8% | -5.2% | +108.3% | -47.9% | |
| – | -9.2% | +161.9% | -0.5% | -9.9% | -9.9% | -14.1% | -12.1% | +26.6% | -22.0% | +46.4% | -22.0% | |
| – | – | +225.0% | -30.4% | +25.6% | +11.8% | +0.2% | -6.9% | +1.8% | -25.4% | +5.9% | -66.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +26.5% | +22.1% | +48.4% | -19.9% | +37.8% | -8.8% | +16.3% | +60.3% | +40.2% | -25.5% | -24.9% | |
| – | +45.0% | +35.1% | +64.7% | -23.0% | +49.6% | -9.1% | +20.4% | +69.3% | +43.6% | -26.3% | -28.5% | |
| – | +18.2% | -1.4% | +20.2% | +3.4% | +3.3% | +3.4% | +3.0% | +1.9% | -4.0% | -4.3% | +13.6% | |
| – | +69.7% | +49.5% | +52.1% | -42.2% | +43.8% | -6.2% | +83.3% | +166.3% | -53.0% | +64.4% | -11.4% | |
| – | -11.9% | +182.5% | -8.4% | -6.2% | -13.4% | -16.0% | -16.9% | +16.0% | -43.8% | +102.4% | -19.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +22.0% | +19.1% | +0.0% | +0.0% | +0.2% | +0.1% | +22.3% | +8.8% | +0.0% | +22.0% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.